Drugs / mRNA-1283.529
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05137236 | Dec 2021 → Mar 2023 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1283.529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05137236 ↗ |
| Modality | Messenger RNA (mRNA) | “A subsequent, open-label study (part B) evaluated the safety and immunogenicity of a monovalent Omicron BA.1 vaccine, mRNA-1283.529 (5 and 10 µg).” PMID 39792478 ↗ Apr 2025 |
| Route | Intramuscular | “Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.” NCT05137236 ↗ |